Group of TBIL Dosing intervals Maintenance Doses Probability of Ctrough attainment Probability of Ctrough attainment Probability of Ctrough attainment Probability of Ctrough attainment Probability of Ctrough attainment Probability of Ctrough attainment Probability of Ctrough attainment
Intravenous administration
Intravenous administration
Intravenous administration
Oral administration
Oral administration
Oral administration
<0.5 mg/L 0.5-5.0 mg/L >5.0 mg/L <0.5 mg/L 0.5-5.0 mg/L >5.0 mg/L
TBIL-2 q12h 200mg 0.0% 11.7% 88.3% 0.0% 15.9% 84.1%
150mg 0.0% 22.9% 77.1% 0.0% 30.8% 69.2%
100mg 0.0% 53.2% 46.8% 0.0% 63.6% 36.4%
50mg 0.0% 95.2% 4.8% 0.1% 97.8% 2.1%
qd 200mg 0.0% 59.7% 40.3% 0.0% 69.6% 30.4%
150mg 0.0% 80.7% 19.3% 0.0% 87.3% 12.7%
100mg 0.2% 95.9% 3.9% 0.3% 97.8% 1.9%
50mg 2.3% 97.6% 0.0% 4.0% 96.0% 0.0%
TBIL-3 q12h 200mg 0.0% 6.2% 93.8% 0.0% 7.6% 92.4%
150mg 0.0% 9.2% 90.8% 0.0% 11.7% 88.3%
100mg 0.0% 17.4% 82.6% 0.0% 24.0% 76.0%
50mg 0.0% 65.3% 34.7% 0.0% 76.2% 23.8%
qd 200mg 0.0% 20.9% 79.1% 0.0% 27.2% 72.8%
150mg 0.0% 37.2% 62.8% 0.0% 47.2% 52.8%
100mg 0.0% 70.1% 29.9% 0.0% 80.5% 19.5%
50mg 0.0% 98.7% 1.3% 0.1% 99.6% 0.4%